These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2872130)

  • 1. Clinical and serological reactions after immunization of children in Ghana, West Africa, with the Japanese acellular pertussis vaccine.
    Biritwum RB; Isomura S; Ofosu-Amaah S; Sato Y
    Dev Biol Stand; 1985; 61():539-43. PubMed ID: 2872130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japanese clinical trials with Takeda acellular pertussis vaccine.
    Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
    Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results with a new DTP vaccine in Japan.
    Kimura M; Hikino N
    Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients.
    Isomura S; Suzuki S; Sato Y
    Dev Biol Stand; 1985; 61():531-7. PubMed ID: 3914964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants.
    Blennow M; Granström M
    Pediatrics; 1989 Jul; 84(1):62-7. PubMed ID: 2544850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children.
    Sato Y; Sato H
    Dev Biol Stand; 1985; 61():367-72. PubMed ID: 3835079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of acellular pertussis vaccine in Sweden. An attempt to solve the problem of pertussis vaccination.
    Olin P
    Ann Sclavo Collana Monogr; 1986; 3(1-2):165-72. PubMed ID: 2892504
    [No Abstract]   [Full Text] [Related]  

  • 8. A modified schedule for routine pertussis immunization.
    Swartz TA; Roumiantzeff M; Peyron L; Stopler T; Kanaaneh H; Leitner L; Goldblum N
    Dev Biol Stand; 1985; 61():289-96. PubMed ID: 2872116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
    Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
    Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against pertussis by Takeda's acellular pertussis vaccine: household contact studies in Kawasaki City, Japan.
    Kato T; Kaku H; Arimoto Y
    Tokai J Exp Clin Med; 1988; 13 Suppl():35-8. PubMed ID: 3078808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical studies on efficacy and safety of acellular pertussis vaccine.
    Isomura S
    Tokai J Exp Clin Med; 1988; 13 Suppl():39-43. PubMed ID: 3078809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
    Hallander HO; Ljungman M; Storsaeter J; Gustafsson L
    APMIS; 2009 Nov; 117(11):797-807. PubMed ID: 19845530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
    Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
    APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
    Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
    CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany.
    Juretzko P; von Kries R; Hermann M; Wirsing von König CH; Weil J; Giani G
    Clin Infect Dis; 2002 Jul; 35(2):162-7. PubMed ID: 12087522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
    Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
    Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
    Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
    Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of acellular pertussis vaccine in young infants.
    Aoyama T; Iwata T; Iwai H; Murase Y; Saito T; Akamatsu T
    J Infect Dis; 1993 Feb; 167(2):483-6. PubMed ID: 8421187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.
    Lacombe K; Yam A; Simondon K; Pinchinat S; Simondon F
    Vaccine; 2004 Dec; 23(5):623-8. PubMed ID: 15542182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada.
    Bettinger JA; Halperin SA; De Serres G; Scheifele DW; Tam T
    Pediatr Infect Dis J; 2007 Jan; 26(1):31-5. PubMed ID: 17195702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.